Ionova Life Sciences

Ionova Life Sciences is a clinical-stage biopharmaceutical company focused on developing next-generation small molecule precision medicines for oncology. The company utilizes its internal expertise in medicinal chemistry and translational medicine to target well-validated oncogenic drivers with high selectivity. Its lead candidate, INV-1122, is a potent FGFR inhibitor currently being evaluated in clinical trials for patients with FGFR-altered solid tumors. Additionally, Ionova is advancing INV-1007, a selective RET inhibitor, to address resistance mechanisms in lung and thyroid cancers. With operations in both China and the United States, Ionova aims to deliver transformative therapies to global markets.